Resource clarifies NSF GMP, USP Verified, and FDA cGMP standards and how GMP certification drives trust, retailer ...

Scale-up involves increasing pump sizes, reactor volumes, and flow rates—but the process control logic and system ...

"The CMS pilot program could establish a federally supported cannabinoid treatment category before FDA botanical drug development standards are completed-potentially redefining how medicine enters the ...

Michelle Dennis, QC Microbiology Application Specialist with MilliporeSigma and member of the PDA Week 2026 planning ...

The most likely Sai Parenterals IPO allotment date is 28 March 2026. However, as Saturday falls on 28 March, the company may ...

In line with the drug manufacturing practices followed in regulated geographies, Central Drug Standards Control Organization (CDSCO) has successfully concluded training sessions for drug inspectors on ...

Sai Parenteral’s IPO has received a weak response, being subscribed only 0.42 times by Day 2. The ₹409 crore IPO includes a ...

Independent oversight reinforces manufacturing, supply chain integrity, and federal readiness for a platform designed to scale across multiple ...

Upon approval, Rocket has been awarded a priority review voucher, which currently fetch around $200m on the secondary market.

Almirall has signed a collaboration and licensing agreement with Shanghai Huaota Biopharmaceutical, a subsidiary of Zhejiang Huahai Pharmaceutical, to develop a monoclonal antibody candidate for ...

Sai Parenteral IPO sees robust subscription in primary market. Sai Parenteral initial public offer (IPO) got subscribed 63 ...

Latest grey market premium (GMP) trends suggest a positive listing gain for investors who bid for Amir Chand Jagdish Kumar ...